Jubilant Pharmova share price has plunged 4% and is presently trading at Rs 1,120.1.
Meanwhile, the BSE HEALTHCARE index is at 43,814.5 (down 1.0%).
Among the top losers in the BSE HEALTHCARE index today are KIMS (down 9.6%) and CAPLIN POINT (down 3.3%).
DR. LAL PATHLABS (up 0.7%) and Cadila Healthcare are among the top gainers today.
Over the last one year, Jubilant Pharmova has moved up from Rs 435.6 to Rs 1,120.1, registering a gain of Rs 684.5 (up 157.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,428.9 to 43,814.5, registering a gain of 54.1% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 157.1%), SUVEN PHARMACEUTICALS (up 105.3%) and Glenmark Pharma (up 96.0%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 83,002.1 (down 1.5%).
The top losers among the BSE Sensex today are Asian Paints (down 3.0%) and Tata Motors (down 2.9%). The most traded stocks in the BSE Sensex are HDFC Bank and Tata Steel.
In the meantime, NSE Nifty is at 25,452.9 (down 1.3%). BPCL and Bajaj Auto are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,512.1 to 83,002.1, registering a gain of 17,490.0 points (up 26.7%).
Jubilant Pharmova net profit grew 6410.8% YoY to Rs 4,818 million for the quarter ended June 2024, compared to a profit of Rs 74 million a year ago. Net sales rose 9.1% to Rs 17,317 million during the period as against Rs 15,869 million in April-June 2023.
For the year ended March 2024, Jubilant Pharmova reported 212.0% increase in net profit to Rs 727 million compared to net loss of Rs 649 million during FY23. Revenue of the company grew 6.7% to Rs 67,029 million during FY24.
The current Price to earnings ratio of Jubilant Pharmova, based on rolling 12 month earnings, stands at 34.1.
Equitymaster requests your view! Post a comment on "Jubilant Pharmova Plunges 4%; BSE HEALTHCARE Index Down 1.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!